MIFE News & Analysis

Supreme Court Allows Mail-Order Mifepristone Pending Appeal Decision

The Supreme Court has allowed mail orders of the abortion drug mifepristone pending an appeal regarding its distribution methods. The ruling follows a ban by the 5th Circuit U.S. Court of Appeals. Two drug manufacturers, Danco Laboratories and GenBioPro, requested the Supreme Court lift the mail-order ban, which was initially imposed on May 1. Justices Thomas and Alito dissented, questioning the legality and implications of distributing mifepristone. This ruling may impact regulatory responses and market positions of the involved companies.